Haleon (HLN) Return on Sales (2021 - 2023)

Haleon (HLN) posted Return on Sales of 0.0% for Q4 2023, down 10.55% on a QoQ basis from 0.0% in Q2 2023, and little changed year-over-year from 0.0% in Q4 2022.

Haleon (HLN) Return on Sales (2021 - 2023) Analysis & Trends

Haleon's Return on Sales history runs 3 years deep, the most recent figure standing at 0.0% for Q4 2023.

  • Quarterly Return on Sales changed 0.0% year-over-year to 0.0% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 0.0% (changed N/A YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
  • Return on Sales was 0.0% for Q4 2023 at Haleon, down from 0.0% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.0% in Q4 2022 and bottomed at 0.0% in Q4 2023.
  • A 3-year average of 0.0% and a median of 0.0% in 2021 frame the typical range for Return on Sales.
  • Peak annual rise in Return on Sales reached 0 bps in 2022, while the deepest fall reached 0 bps in 2022.
  • Haleon's Return on Sales stood at 0.0% in 2021, then soared by 76 bps to 0.0% in 2022, then sank by 54 bps to 0.0% in 2023.
  • Business Quant data shows HLN's Return on Sales at 0.0% in Q4 2023, 0.0% in Q2 2023, and 0.0% in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 0.00%
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 0.00%
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -0.01%
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 0.00%
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 0.00%
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 0.00%
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 0.00%
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn 0.00%

Historic Data

Download Data
DateValue
Dec 31, 2023 0.00%
Jun 30, 2023 0.00%
May 3, 2023 0.00%
Dec 31, 2022 0.00%
Dec 31, 2021 0.00%